Published in Eur Heart J on April 27, 2006
Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest (2010) 2.35
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int (2007) 2.03
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis (2013) 1.90
Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis (2007) 1.26
Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol (2010) 1.23
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther (2009) 1.05
Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.03
An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med (2014) 1.02
Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis (2012) 1.00
Systemic sclerosis-associated pulmonary arterial hypertension. Chest (2013) 1.00
Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest (2014) 0.96
Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One (2012) 0.95
Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med (2011) 0.95
Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med (2007) 0.93
Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol (2011) 0.93
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther (2012) 0.90
Lung involvement in systemic sclerosis. Presse Med (2010) 0.90
Biomarkers in systemic sclerosis. Biomark Med (2010) 0.90
Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol (2010) 0.87
Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin (2012) 0.86
Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int (2013) 0.85
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther (2013) 0.83
Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol (2008) 0.82
Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag (2014) 0.82
Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ (2013) 0.81
Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med (2009) 0.81
Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Semin Arthritis Rheum (2015) 0.81
Treatment-related biomarkers in pulmonary hypertension. Am J Respir Cell Mol Biol (2015) 0.80
Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. Mediators Inflamm (2009) 0.80
Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol (2009) 0.80
The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep (2010) 0.80
Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol (2013) 0.79
N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 0.78
2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.77
Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum (2013) 0.77
Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. Pulm Circ (2011) 0.76
Challenges in the diagnosis and treatment of juvenile systemic sclerosis. Nat Rev Rheumatol (2011) 0.76
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension. Ann Thorac Med (2014) 0.75
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases. Ann Thorac Med (2014) 0.75
Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis. J Clin Rheumatol Musculoskelet Med (2010) 0.75
Novel biomarkers for pulmonary arterial hypertension. Respir Res (2016) 0.75
Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria. Reumatologia (2016) 0.75
N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment. Rheumatol Int (2008) 0.75
Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol (2015) 0.75
[Pulmonary arterial hypertension in collagenoses]. Z Rheumatol (2009) 0.75
[Laboratory diagnostics for systemic sclerosis]. Z Rheumatol (2007) 0.75
CT-proET1 predicts pulmonary hemodynamics in Scleroderma-associated pulmonary hypertension. Clin Res Cardiol (2015) 0.75
Impact of systemic sclerosis on electromechanical characteristics of the heart. Heart Vessels (2010) 0.75
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
A myocardial lineage derives from Tbx18 epicardial cells. Nature (2008) 6.15
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2008) 3.67
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS (2005) 2.96
A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80
Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS (2004) 2.76
Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem (2003) 2.63
Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem (2003) 2.35
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax (2013) 2.17
CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem (2006) 1.96
Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl (2007) 1.87
Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol (2006) 1.87
CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell (2004) 1.83
Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther (2005) 1.81
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am J Respir Crit Care Med (2010) 1.76
Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol (2006) 1.73
Flexibility and diversity in consultant careers. Clin Med (2002) 1.71
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS (2006) 1.71
Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol (2006) 1.70
Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. Am J Pathol (2002) 1.68
Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum (2009) 1.65
Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis (2010) 1.65
Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J (2002) 1.64
Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol (2009) 1.60
CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp Cell Res (2006) 1.57
Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts. Respir Res (2004) 1.55
Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem (2004) 1.52
Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med (2008) 1.52
Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol (2004) 1.52
Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum (2007) 1.51
Telomeres are shorter in myocardial infarction patients compared to healthy subjects: correlation with environmental risk factors. J Mol Med (Berl) (2010) 1.51
Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis (2013) 1.51
Retracted GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest (2008) 1.46
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol (2007) 1.46
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum (2007) 1.45
Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum (2007) 1.42
Regulation of collagen type I in vascular smooth muscle cells by competition between Nkx2.5 and deltaEF1/ZEB1. Mol Cell Biol (2004) 1.32
Scleroderma--clinical and pathological advances. Best Pract Res Clin Rheumatol (2004) 1.31
Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr (2011) 1.31
Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum (2006) 1.30
Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem (2003) 1.29
Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med (2002) 1.27
Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol (2014) 1.26
Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum (2009) 1.25
CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology (2004) 1.25
Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem (2003) 1.24
Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol (2010) 1.23
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum (2007) 1.23
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis (2012) 1.21
Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo. J Cell Sci (2010) 1.21
Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.20
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis (2012) 1.19
FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell (2007) 1.19
Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS (2010) 1.17
Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum (2007) 1.16
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum (2008) 1.15
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J (2008) 1.13
Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol (2008) 1.13
Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol (2010) 1.12
Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum (2009) 1.11
Rapid diagnosis of smear-negative tuberculosis using immunology and microbiology with induced sputum in HIV-infected and uninfected individuals. PLoS One (2007) 1.10
Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford) (2013) 1.10
Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol (2010) 1.09
Systemic amyloidosis in England: an epidemiological study. Br J Haematol (2013) 1.08
Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res (2013) 1.08
Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum (2013) 1.07